Ronald L Brazg
Overview
Explore the profile of Ronald L Brazg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
529
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bailey T, Liljenquist D, Denham D, Brazg R, Ioacara S, Masciotti J, et al.
Diabetes Technol Ther
. 2025 Jan;
PMID: 39869118
The implanted Eversense Continuous Glucose Monitoring (CGM) System transitioned from 90- to 180- to 365-day durations marketed today. This report summarizes the 365-day clinical study. ENHANCE was a prospective, multicenter...
2.
Garg S, Grunberger G, Weinstock R, Lawson M, Hirsch I, DiMeglio L, et al.
Diabetes Technol Ther
. 2022 Dec;
25(1):1-12.
PMID: 36472543
To evaluate safety and effectiveness of MiniMed™ 670G hybrid closed loop (HCL) in comparison with continuous subcutaneous insulin infusion (CSII) therapy for 6 months in persons with type 1 diabetes...
3.
Garg S, Liljenquist D, Bode B, Christiansen M, Bailey T, Brazg R, et al.
Diabetes Technol Ther
. 2021 Sep;
24(2):84-92.
PMID: 34515521
Use of continuous glucose monitoring (CGM) systems is being rapidly adopted as standard of care for insulin-requiring patients with diabetes. The PROMISE study (NCT03808376) evaluated the accuracy and safety of...
4.
Bergenstal R, Johnson M, Aroda V, Brazg R, Dreon D, Frias J, et al.
J Diabetes Sci Technol
. 2021 May;
16(5):1167-1173.
PMID: 34008442
Objective: CeQur Simplicity™ (CeQur, Marlborough, MA) is a 3-day insulin delivery patch designed to meet mealtime insulin requirements. A recently reported 48-week, randomized, multicenter, interventional trial compared efficacy, safety and...
5.
Bergenstal R, Peyrot M, Dreon D, Aroda V, Bailey T, Brazg R, et al.
Diabetes Technol Ther
. 2019 Apr;
21(5):273-285.
PMID: 31025878
Barriers to mealtime insulin include complexity, fear of injections, and lifestyle interference. This multicenter, randomized controlled trial evaluated efficacy, safety, and self-reported outcomes in adults with type 2 diabetes, inadequately...
6.
Klonoff D, Parkes J, Kovatchev B, Kerr D, Bevier W, Brazg R, et al.
Diabetes Care
. 2018 Jun;
41(8):1681-1688.
PMID: 29898901
Objective: Cleared blood glucose monitors (BGMs) for personal use may not always deliver levels of accuracy currently specified by international and U.S. regulatory bodies. This study's objective was to assess...
7.
Garg S, Weinzimer S, Tamborlane W, Buckingham B, Bode B, Bailey T, et al.
Diabetes Technol Ther
. 2017 Jan;
19(3):155-163.
PMID: 28134564
Background: The safety and effectiveness of the in-home use of a hybrid closed-loop (HCL) system that automatically increases, decreases, and suspends insulin delivery in response to continuous glucose monitoring were...
8.
Brazg R, Klaff L, Sussman A
J Diabetes Sci Technol
. 2016 Jun;
10(6):1414-1415.
PMID: 27271844
No abstract available.
9.
Garg S, Brazg R, Bailey T, Buckingham B, Slover R, Klonoff D, et al.
Diabetes Technol Ther
. 2014 Jan;
16(3):125-30.
PMID: 24405492
Background: The ASPIRE in-clinic study established that automatic suspension of insulin with the threshold suspend (TS) feature reduces the duration of induced hypoglycemia. The study's crossover design allowed the effects...
10.
Brazg R, Klaff L, Parkin C
J Diabetes Sci Technol
. 2013 Feb;
7(1):144-52.
PMID: 23439170
Background: Blood glucose data are frequently used in clinical decision making, thus it is critical that self-monitoring of blood glucose (SMBG) systems consistently provide accurate results. Concerns about SMBG accuracy...